Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26730038 | 0.86 | ITGB3 (0.40) | ITGB3ITGA2BPTGIR | |
| SCHEMBL26209238 | 0.86 | ITGB3 (0.40) | ITGB3ITGA2BPTGIR | |
| SCHEMBL22329119 | 0.81 | KHK (0.31) | ITGB3ITGA2BPOLA1CDC25A | |
| SCHEMBL21191170 | 0.79 | — | — | |
| SCHEMBL29173291 | 0.78 | PDK2 (0.33) | ITGB3ITGA2BPDK2 | |
| SCHEMBL22329104 | 0.78 | MAPT (0.30) | MAPT | |
| SCHEMBL21146867 | 0.78 | MAPT (0.30) | MAPT | |
| SCHEMBL8948689 | 0.74 | CYP3A4 (0.35) | ITGB3ITGA2BCYP1A2PDK2PTGIR | |
| SCHEMBL8948647 | 0.73 | ATM (0.52) | ITGB3ITGA2BPDK2PTGIR | |
| SCHEMBL15764113 | 0.73 | CYP1A2 (0.38) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| WO-2018090862-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | DPYD, DHPS, HPRT1 | ITGB3 4803/4885ITGA2B 4668/4885CYP1A2 195/4885 |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, TYMP, DHPS | ITGB3 4759/4885ITGA2B 4686/4885CYP1A2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.